Heart Failure

 

The Practical Cardiology(TM) Heart Failure clinical resource center is an information hub for the latest in heart failure and heart failure management. With a focus on heart failure with reduced and preserved ejection fraction (HFrEF and HFpEF) this page features content including articles, videos, podcasts, and clinician-authored columns on FDA approvals, studies, guideline updates, and more.

Cardiology Month in Review: September 2021

September 25, 2021

September's cardiology month in review features FDA news relted to empagliflozin and tofacitinib, a study into the potential impact of sacubitril/valsartan's label expansion, and a study from HFSA 2021.

Digital Apps Could Improve Outcomes, Adherence Among Patients With Heart Failure

September 17, 2021

Data from the CONNECT-HF trial from HFSA 2021 suggest use of a digital tool designed to improve adherence could contribute to improving outcomes among patients discharged from the hospital with heart failure with reduced ejection fraction.

Matthew Budoff, MD: Need for Greater Uptake of Newer Medications

September 15, 2021

Matthew Budoff, MD, discusses what he views as hurdles to achieving optimal prescription of newer agents in the treatment of cardiometabolic conditions, including diabetes, heart failure, dyslipidemia, and more.

PRESERVED-HF: Dapagliflozin Reduces Symptom Burden, Physical Limitations in HFpEF

September 14, 2021

Presented at HFSA 2021, PRESERVED-HF provides evidence suggesting dapagliflozin use was associated with improvements in KCCQ symptom score and 6-minute walking distance in patients with heart failure with preserved ejection fraction.

ESC Congress 2021: Top Trials Slideshow

August 31, 2021

Every year, ESC Congress provides clinicians and researchers with a glimpse into the latest data from clinical trials. Our editorial staff's top picks for new trials from ESC Congress 2021 conference includes EMPEROR-Preserved, FIGARO-DKD, SSaSS, MASTER DAPT, and the LOOP Study.

Q&A on EMPEROR-Preserved With Javed Butler, MD

August 27, 2021

In an interview with Practical Cardiology, Javed Butler, MD, offers his perspective on the results of EMPEROR-Preserved and reflects on their rapid ascent into the cardiometabolic spotlight, evidenced by headlining trials at ESC Congress for the past 3 years.

EMPEROR-Preserved: Empagliflozin Proves Benefit in HFpEF

August 27, 2021

Results of EMPEROR-Preserved demonstrate use of empagliflozin was associated with a 21% reduction in the composite end point of hospitalization for heart failure and cardiovascular death, with this effect mainly driven by a reduction in hospitalization for heart failure.